240 related articles for article (PubMed ID: 26929601)
21. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim H; Kim CH
Oncotarget; 2017 May; 8(19):31923-31937. PubMed ID: 28404875
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review.
Guo H; Zhou S; Tan L; Wu X; Wu Z; Ran R
Oncotarget; 2017 Jan; 8(2):2550-2557. PubMed ID: 27911280
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma.
Tomizawa Y; Nakajima T; Kohno T; Saito R; Yamaguchi N; Yokota J
Cancer Res; 1998 Dec; 58(23):5478-83. PubMed ID: 9850082
[TBL] [Abstract][Full Text] [Related]
24. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
25. The clinicopathological significance and potential drug target of E-cadherin in NSCLC.
Zhong K; Chen W; Xiao N; Zhao J
Tumour Biol; 2015 Aug; 36(8):6139-48. PubMed ID: 25758052
[TBL] [Abstract][Full Text] [Related]
26. Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients.
Pylkkanen L; Wolff H; Stjernvall T; Tuominen P; Sioris T; Karjalainen A; Anttila S; Husgafvel-Pursiainen K
Int J Oncol; 2002 Feb; 20(2):285-90. PubMed ID: 11788890
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
[TBL] [Abstract][Full Text] [Related]
28. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
29. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
[TBL] [Abstract][Full Text] [Related]
30. [The relationship between FHIT gene promoter methylation and lung cancer risk: a meta-analysis].
Sun Y
Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):233-7. PubMed ID: 24667261
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC.
Xue R; Yang C; Zhao F; Li D
Onco Targets Ther; 2014; 7():1987-96. PubMed ID: 25382980
[TBL] [Abstract][Full Text] [Related]
32. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT.
Wu DW; Hsu NY; Wang YC; Lee MC; Cheng YW; Chen CY; Lee H
Oncogene; 2015 Apr; 34(16):2072-82. PubMed ID: 24909176
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathological significance of aberrant methylation of the fragile histidine triad gene in patients with hepatocellular carcinoma].
Sun Y; Geng XP; Zhu LX; Xiong QR; Qian YB; Dong GY; Li XM
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):609-12. PubMed ID: 16784654
[TBL] [Abstract][Full Text] [Related]
34. Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers.
Lee YC; Wu CT; Shih JY; Jou YS; Chang YL
Br J Cancer; 2004 Jun; 90(12):2378-83. PubMed ID: 15150628
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma.
Chen L; Wang Y; Liu F; Xu L; Peng F; Zhao N; Fu B; Zhu Z; Shi Y; Liu J; Wu R; Wang C; Yao S; Li Y
Sci Rep; 2018 Jan; 8(1):1439. PubMed ID: 29362385
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review.
Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y
Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788
[TBL] [Abstract][Full Text] [Related]
37. FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
Wu DW; Lee MC; Hsu NY; Wu TC; Wu JY; Wang YC; Cheng YW; Chen CY; Lee H
Oncogene; 2015 May; 34(19):2505-15. PubMed ID: 24998847
[TBL] [Abstract][Full Text] [Related]
38. FHIT
Da Silva J; Jouida A; Ancel J; Dalstein V; Routhier J; Delepine G; Cutrona J; Jonquet A; Dewolf M; Birembaut P; Deslée G; Polette M; Nawrocki-Raby B
J Pathol; 2020 Jun; 251(2):187-199. PubMed ID: 32237123
[TBL] [Abstract][Full Text] [Related]
39. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
40. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
